

ASX Release

TALi Digital Appoints David Williams as Non-Executive Director*Former Cochlear Executive Joins Board of Digital Health Pioneer*

TALi Digital Ltd (ASX: TD1, "TALi" or "the Company") has appointed David Williams as a non-executive director, effective immediately.

David Williams brings extensive international and domestic healthcare sector experience including 25 years with Cochlear Limited. David held a number of senior commercial and financial roles with the medical devices leader including as Senior Vice President of Finance & Operations for Cochlear Americas, President of Cochlear Americas (acting) and General Manager, Acoustics. Most recently he was Cochlear's Vice President of Global Customer Experience.

Sue MacLeman, Chair of the board of TALi said: "We are very pleased to welcome David to the board. His experience with a world leading medical devices business will complement the existing board at an important stage in TALi's development and commercialisation."

TALi is part of a rapidly growing global digital therapeutics sector. The Company is in the early stages of its international expansion and currently negotiating potential partnership arrangements in a number of key geographies.

In August this year, TALi announced a Strategic Licensing Agreement with Akili Interactive Labs, Inc., a global leader in digital therapeutics, which will see Akili become the company's exclusive commercialisation partner in the U.S. The Akili agreement is transformational and highly strategic for TALi and is estimated to represent AU\$51 million (US\$37.5 million) in total future contingent milestone payments plus royalties on potential revenues.

Release authorised by:

The Board of TALi Digital Limited

CONTACT**Corporate**

Glenn Smith
TALi Digital Managing Director
1300 082 013
investors@talidigital.com

Investors

Paul McKeon
Investor Relations
0414 596 266
pmckeon@talidigital.com

About TALi Digital

TALi [TALi Digital Limited (ASX: TD1)] is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence and game-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy and places TALi at the forefront of patient experience and early intervention for attention related conditions. We believe in healthy, happier minds – they start here with TALi.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia).

At TALi, our vision is to deliver a personalised digital experience to enhance cognitive care. Learn more at talidigital.com.